Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 355

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 355
---
, the same sample collection process will be carried out in conjunction with local entities as we do not rely on existing reference datasets. Personal DNA and Gut Microbiome Profiling Rewell provides customers with direct access to their DNA and gut microbiome information, enabling more informed long -termhealth decisions aimed at minimizing the risk of chronic disease development. This includes insights into genetic ancestry origins and personal genetic health risks, presented through Polygenic Risk Scores (“PRS”), which provides a measure of disease risk based on genetic factors. Rewell also delivers insights on dietary intolerances, physical activity and rest optimization, and specific nutrient impact on gene function and longevity. For PRS reporting, we apply scores from the PGS Catalog, an open database of polygenic scores (PGS), calculated using low -passgenome (“LPG”) sequencing followed by genotype imputation. LPG technology is a high -throughputsolution that produces low coverage of a whole human genome. Samples are sequenced with Illumina technology at a depth of 1X, generating approximately 3 GB of data per sample and a total of 20million reads per sample. For reference, complete genome coverage is achieved at 40X, whereas LPG covers the genome at 0.5 -1X. The resulting sequencing data (FASTQ) is analyzed with our imputation and analysis platform in AWS to obtain a variant file (VCF) with more than 99% accuracy of genome -widevariants. LPG returns more data and statistical power than microarray technology, making it the reference technology for high -throughputgenomics applications. We employ a genomic imputation pipeline that processes low -coveragewhole genome sequencing data (0.5 - 1Xcoverage) using the GLIMPSE software framework ( https://www.nature.com/articles/s41588 -020-00756-0). The pipeline operates on a high -performancecomputing infrastructure utilizing GRCh37 as the reference genome, with data processing orchestrated through the Nextflow workflow management system. Raw sequencing data undergoes quality control before being aligned to the reference genome, followed by genotype imputation using the 1000 Genomes Phase 3 reference panels. Regarding risks associated with the compilation of the PRS scores, the main risk to mention is the ancestry genetic background, which may or may not modify the PRS utility for a given local population. This risk assessed through our validation protocols with local populations. Additional risks include potential inaccuracies due to the limitations of imputation -basedgenotype predictions, the evolving